simplyStocks
Cytokinetics, Incorporated
CYTK · NASDAQHealthcare
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$7B
P/E ratio
n/a (loss)
Div yield
None
Revenue (FY24)
$19M
Rev. growth
+145%
Net loss (FY24)
-$590M
Cash & investments
$1.22B
Lead drug
aficamten
In plain English
Cytokinetics is a cardiovascular biopharma built on muscle biology. Its lead drug aficamten (brand MYQORZO) — a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy — won approval in the US, EU and China and launched in the US in early 2026, turning a long clinical-stage company into a commercial one. It sells the drug itself in the US and Europe and licenses it to Bayer (Japan) and Sanofi (Greater China), while still burning cash on its pipeline.
In simple terms
What Cytokinetics, Incorporated really sells
Cytokinetics is a cardiovascular biopharma built on muscle biology. Its lead drug aficamten (brand MYQORZO) — a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy — won approval in the US, EU and China and launched in the US in early 2026, turning a long clinical-stage company into a commercial one. It sells the drug itself in the US and Europe and licenses it to Bayer (Japan) and Sanofi (Greater China), while still burning cash on its pipeline.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?